

REMARKS

The foregoing amendments to the specification are made to comply with requirements for patent applications containing nucleotide sequences and/or amino acid sequence disclosures. Accompanying this amendment is the Sequence Listing in both computer readable and paper forms, in compliance with 37 C.F.R. §1.821 along with a statement that the disclosures in the computer readable and paper forms are the same and do not introduce new matter into the disclosure of the application. As explained in the accompanying statement, SEQ ID NO: 1 and SEQ ID NO: 2 do not introduce new matter. The amendments to the specification merely introduce appropriate cross-references to the Sequence Listing, consistent with the United States Patent Office Practice procedures.

Applicants authorize the Patent Office to charge or credit any underpayment or overpayment to Deposit Account No. 13-2855. A copy of this paper is included for this purpose.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6357
(312) 474-6300

January 2, 2004

By:



Mark H. Hopkins, Ph.D.
Reg. No. 44,775